Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leptin Replacement in Lipodystrophy
NCT00005905Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jun 2000
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metreleptin in lipodystrophy, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Metabolic Control Parameters at 4 months. Started Jun 2000; status: completed.
02
Drugs
metreleptin
03
Conditions
lipodystrophy
Beyond the preview
Go deeper on NCT00005905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005905.